The Filing Desk

UnitedHealth

UNH · NYSE · Health Care · Financials, fiscal 2016 to 2025

UNH · Last close · November 19, 2026
$330.48
Value UnitedHealth yourself

UnitedHealth's revenue rose 11.8% to $447.6 billion in fiscal 2025. Its operating margin was 4.2%, down from 8.1% a year earlier. Free cash flow was $16.1 billion, down 22.4%. It paid out $13.5 billion in dividends and buybacks, 84% of free cash flow. The diluted share count fell 1.9%.

UnitedHealth Group Incorporated Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0000731766-26-000062 Updated
Revenue
$447.6B
11.8%
Operating margin
4.2%
3.8 pts
Net income
$12.1B
16.3%
Free cash flow
$16.1B
22.4%
Return on capital
11.2%
6.8 pts
Market cap
$298.1B
Nov 19 close
P/E
18.9x
On $17.52 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Total debt is the balance sheet's long-term debt plus its current debt line.

Charts show fiscal years, from the 10-K filings.

What UnitedHealth does

UnitedHealth runs two businesses. UnitedHealthcare sells health insurance to employers, individuals, people on Medicare and people in state Medicaid programs. Optum provides health care, data and technology services, and pharmacy services to patients, doctors and hospitals, other health plans, employers, governments and drug companies.

It reports four segments: Optum Health, which delivers primary, specialty and other care and runs Optum Bank; Optum Insight, which sells data, software and consulting to hospitals, health plans and states; Optum Rx, which manages prescription drug benefits and runs pharmacies; and UnitedHealthcare. Premiums from insurance products, where it takes on the cost of members' care, make up nearly 80% of revenue. Premiums from the Centers for Medicare & Medicaid Services (CMS), which administers the Medicare Advantage program, were 44% of 2025 revenue, mostly through its Medicare plans. UnitedHealth says its competitors range from startups to large global companies, both for-profit and non-profit.

At the end of 2025 UnitedHealthcare served 29.7 million people through employer and individual plans, 8.4 million through Medicare Advantage plans and nearly 7.4 million through Medicaid and other state programs. Optum Rx managed $188 billion in drug spending in 2025. The company had more than 390,000 employees, nearly 165,000 of them clinical professionals. On January 1, 2026, it moved Optum Financial, including Optum Bank, from Optum Health into Optum Insight.

Its biggest risks, as it describes them

  • Misjudging or failing to manage medical costs, which could cut the profit on its insurance products.
  • Its reliance on government health programs, which brings risks from funding changes, payment adjustments, audits and investigations.
  • Failing to keep good relationships with doctors, hospitals and other providers.
  • Frequent lawsuits and government investigations over how it designs and delivers its products and services.
  • Regulatory and operating risks in its pharmacy businesses that differ from those in the rest of the company.
From UnitedHealth's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 6.9% a year and net income 6.2% a year, as buybacks cut the share count by 6%.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments23.927.929.629.128.1
Debt incl. finance leases46.057.662.576.978.4
Net debt (negative means net cash)22.129.732.947.850.3
Net debt to EBITDA0.8x0.9x0.9x1.3x2.2x
Debt to equity0.6x0.7x0.7x0.8x0.8x
Interest coverage14.4x13.6x10.0x8.3x4.7x
Current ratio0.8x0.8x0.8x0.8x0.8x
Quick ratio0.8x0.7x0.8x0.8x0.8x
US$ billions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project UnitedHealth's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought UnitedHealth shares on the open market, and 1 insider sold $944,910.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 21, 2026Patrick Hugh ConwayChief Executive Officer, OptumSold1,169$390.00$455,910Form 4
Aug 5, 2026Patrick Hugh ConwayChief Executive Officer, OptumSold500$410.00$205,000Form 4
Apr 23, 2026Patrick Hugh ConwayChief Executive Officer, OptumSold800$355.00$284,000Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 95 of 97 of 9
Rule of 4021.6%12.9%15.4%
Altman Z''2.011.911.41
Accruals ratio−2.6%−3.4%−2.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassFailPass
Current ratio rosePassPassFail
Share count didn't risePassPassPass
Gross margin roseFailFailPass
Revenue rose relative to assetsFailFailPass
F-score6 of 95 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put UnitedHealth side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
UnitedHealthFY2511.8%4.2%3.6%11.2%2.2x7
HCA HealthcareFY257.1%—10.2%22.3%3.0x6Compare
Johnson & JohnsonFY256.0%—20.9%28.6%0.7x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue184.8201.2226.2242.2257.1287.6324.2371.6400.3447.6
Revenue growth17.6%8.8%12.5%7.0%6.2%11.8%12.7%14.6%7.7%11.8%
Gross profit160.4177.0199.2214.0226.4256.6290.5332.9353.6396.9
Research and development——————————
Operating income12.915.217.319.722.424.028.432.432.319.0
Net income7.010.612.013.815.417.320.122.414.412.1
Diluted EPS (US$)7.2510.7212.1914.3316.0318.0821.1823.8615.5113.23
Diluted shares (millions)968985983966961956950938929911
Cash flow
Cash from operations9.813.615.718.522.222.326.229.124.219.7
Capital expenditure1.72.02.12.12.12.52.83.43.53.6
Free cash flow8.111.613.716.420.119.923.425.720.716.1
Dividends paid2.32.83.33.94.65.36.06.87.57.9
Share buybacks1.31.54.55.54.25.07.08.09.05.5
Acquisitions1.82.16.08.37.14.821.510.113.44.5
Stock-based compensation0.50.60.60.70.70.80.91.11.01.0
Balance sheet at fiscal year end
Cash and short-term investments13.315.514.314.219.823.927.929.629.128.1
Debt incl. finance leases33.031.736.640.743.546.057.662.576.978.4
Total assets122.8139.1152.2173.9197.3212.2245.7273.7298.3309.6
Total liabilities82.687.096.0111.7126.8135.7159.4174.8195.7207.9
Shareholders' equity38.249.854.360.468.375.081.594.498.3100.1
Margins and ratios
Gross margin86.8%88.0%88.1%88.4%88.0%89.2%89.6%89.6%88.3%88.7%
Operating margin7.0%7.6%7.7%8.1%8.7%8.3%8.8%8.7%8.1%4.2%
Net margin3.8%5.2%5.3%5.7%6.0%6.0%6.2%6.0%3.6%2.7%
Free cash flow margin4.4%5.8%6.0%6.8%7.8%6.9%7.2%6.9%5.2%3.6%
Rule of 40 (growth + FCF margin)22.0%14.6%18.5%13.8%14.0%18.8%19.9%21.6%12.9%15.4%
Return on capital13.9%18.9%18.9%19.1%19.0%20.1%21.4%21.6%17.9%11.2%
Return on equity19.5%24.0%23.0%24.1%23.9%24.1%25.7%25.4%14.9%12.2%
Return on assets6.0%8.1%8.2%8.5%8.3%8.4%8.8%8.6%5.0%4.0%
Net debt to EBITDA1.3x0.9x1.1x1.2x0.9x0.8x0.9x0.9x1.3x2.2x
US$ billions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: UnitedHealth's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with UnitedHealth.